Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Silence Therapeutics Provides Year-end Update

December 20, 2010 By Bio-Medicine.Org

LONDON, Dec. 21, 2010 /PRNewswire/ — Silence Therapeutics plc
(AIM: SLN) (“Silence” or the “Company”), a leading global
biotechnology company dedicated to the discovery, development and
delivery of targeted, systemic RNA interference (RNAi) therapeutics
for the treatment of serious diseases, today provides a year-end
update on trading and the offer-period.

Phil Haworth, CEO of Silence Therapeutics, comments: “2010
has been an exciting year for Silence Therapeutics. The Company is
delighted with the clinical progress it has made with Atu027 and
our Phase I trial continues on track.  In addition, our
partner, Quark Pharmaceuticals, has made significant progress with
QPI-1002, both in advancing the product into Phase II trials and in
partnering it with Novartis.  We are pleased to be announcing
a milestone payment from Quark today.”

Offer Period

Further to the announcement dated 6th September 2010, Silence
confirms that it remains in an offer period. The Company continues
to explore a variety of strategic opportunities.

Atu027 Phase I trial

During the course of 2010, excellent progress has been made with
the Company’s flagship Phase I trial of Atu027 in patients with
solid tumours. This trial remains on track and, to date, 18
patients have been treated. Trial completion is expected in the
second half of 2011.

Milestone from Quark

Silence is pleased to announce today that it has reached
agreement with Quark Pharmaceuticals Inc. (“Quark”) whereby Silence
is due to receive milestone payments of up to $1.5 million in
relation to the option agreement signed between Quark and Novartis
for QPI-1002. Silence anticipates that its share of future
milestone payments relating to Quark’s license agreement with
Novartis could reach $80 million.

  • Based on Silence’s AtuRNAi technology, Quark is developing its
    QPI-1002 for the prevention of acute kidney i

    ‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech